Literature DB >> 15102491

Beta 2-adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis.

Jacques De Keyser1, Esther Zeinstra, Jop Mostert, Nadine Wilczak.   

Abstract

Relapses of multiple sclerosis (MS) are considered to be the clinical expression of acute T-cell-mediated inflammatory demyelinating lesions disseminated in the CNS, whereas disease progression seems to result from widespread axonal degeneration. The pathophysiology of both disease components is incompletely understood. Astrocytes in MS lack beta(2)-adrenoceptors, which via cAMP-mediated processes inhibit the expression of major histocompatibility (MHC) class II molecules and stimulate glycogenolysis in normal conditions. In a pro-inflammatory CNS environment this beta(2)-adrenoceptor defect might allow astrocytes to transform into facultative antigen-presenting cells that can initiate the inflammatory cascade. The same receptor defect might impair astrocytic glycogenolysis, which normally generates lactate that is transported to axons as an energy source. Failure of axonal energy metabolism might result in axonal degeneration through mechanisms that involve intra-axonal accumulation of Ca(2+) ions and mitochondrial dysfunction. If this hypothesis is correct, therapies designed to elevate cAMP levels in astrocytes should reduce or prevent both relapses and progression of MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102491     DOI: 10.1016/j.tips.2003.12.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  10 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Functional plasticity of macrophages: reversible adaptation to changing microenvironments.

Authors:  Robert D Stout; Jill Suttles
Journal:  J Leukoc Biol       Date:  2004-06-24       Impact factor: 4.962

Review 3.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 4.  Astrocytes as secretory cells of the central nervous system: idiosyncrasies of vesicular secretion.

Authors:  Alexei Verkhratsky; Michela Matteoli; Vladimir Parpura; Jean-Pierre Mothet; Robert Zorec
Journal:  EMBO J       Date:  2016-01-12       Impact factor: 11.598

5.  Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis.

Authors:  Marcus Koch; Geeta S M Ramsaransing; Alexander V Arutjunyan; Michael Stepanov; Albert Teelken; Dorothea J Heersema; Jacques De Keyser
Journal:  J Neurol       Date:  2005-11-14       Impact factor: 4.849

6.  Neuroimmune interaction in inflammatory diseases.

Authors:  Peyman Otmishi; Joshiah Gordon; Seraj El-Oshar; Huafeng Li; Juan Guardiola; Mohamed Saad; Mary Proctor; Jerry Yu
Journal:  Clin Med Circ Respirat Pulm Med       Date:  2008-04-29

Review 7.  Astrocytic vesicle mobility in health and disease.

Authors:  Maja Potokar; Nina Vardjan; Matjaž Stenovec; Mateja Gabrijel; Saša Trkov; Jernej Jorgačevski; Marko Kreft; Robert Zorec
Journal:  Int J Mol Sci       Date:  2013-05-27       Impact factor: 5.923

8.  The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.

Authors:  Jop Mostert; Thea Heersema; Manju Mahajan; Jeroen Van Der Grond; Mark A Van Buchem; Jacques De Keyser
Journal:  ISRN Neurol       Date:  2013-07-29

9.  IGF-1 regulates cAMP levels in astrocytes through a beta2-adrenergic receptor-dependant mechanism.

Authors:  Daniel Chesik; Nadine Wilczak; Jacques De Keyser
Journal:  Int J Med Sci       Date:  2008-08-06       Impact factor: 3.738

Review 10.  Noradrenergic Hypothesis Linking Neurodegeneration-Based Cognitive Decline and Astroglia.

Authors:  Giampiero Leanza; Rosario Gulino; Robert Zorec
Journal:  Front Mol Neurosci       Date:  2018-07-27       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.